Investors & Media

For media inquiries,
please contact:

Chris Erdman
MacDougall Biomedical Communications
781-235-3060

In the News

Dicerna has been featured frequently in the media. Please browse select news coverage to read more about Dicerna and its next generation RNAi approach to developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules.